Consensus recommendation for a diagnostic guideline for acid sphingomyelinase deficiency

Background: Acid sphingomyelinase deficiency (ASMD) is a rare, progressive, and often fatal lysosomal storage disease. The underlying metabolic defect is deficiency of the enzyme acid sphingomyelinase that results in progressive accumulation of sphingomyelin in target tissues. ASMD manifests as a sp...

ver descrição completa

Detalhes bibliográficos
Autores: McGovern, Margaret M., Vici, Carlo Dionisi, Giugliani, Roberto, Hwu, Paul, Lidove, Olivier, Lukacs, Zoltan, Mengel, Karl Eugen, Mistry, Pramod, Schuchman, Edward, Wasserstein, Melissa P.
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2017
País:Brasil
Recursos:Universidade Federal do Rio Grande do Sul (UFRGS)
Repositorio:Repositório Institucional da UFRGS
Idioma:inglés
OAI Identifier:oai:www.lume.ufrgs.br:10183/195931
Acesso em linha:http://hdl.handle.net/10183/195931
Access Level:acceso abierto
Palavra-chave:Guia de prática clínica
Consenso
Doenças de Niemann-Pick
Acid sphingomyelin deficiency
Lysosomal storage disorder
Niemann-Pick disease types A and B
Descrição
Resumo:Background: Acid sphingomyelinase deficiency (ASMD) is a rare, progressive, and often fatal lysosomal storage disease. The underlying metabolic defect is deficiency of the enzyme acid sphingomyelinase that results in progressive accumulation of sphingomyelin in target tissues. ASMD manifests as a spectrum of severity ranging from rapidly progressive severe neurovisceral disease that is uniformly fatal to more slowly progressive chronic neurovisceral and chronic visceral forms. Disease management is aimed at symptom control and regular assessments for multisystem involvement. Purpose and methods: An international panel of experts in the clinical and laboratory evaluation, diagnosis, treatment/management, and genetic aspects of ASMD convened to review the evidence base and share personal experience in order to develop a guideline for diagnosis of the various ASMD phenotypes. Conclusions: Although care of ASMD patients is typically provided by metabolic disease specialists, the guideline is directed at a wide range of providers because it is important for primary care providers (e.g., pediatricians and internists) and specialists (e.g., pulmonologists, hepatologists, and hematologists) to be able to identify ASMD.